AzTrials
AzTrials

Efficacy and SafetyNCT06351735

Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis

An observational study of Efficacy and Safety, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, affects motor neurons, causing progressive muscle atrophy and weakness. Current treatments are ineffective, with most patients dying within 3-5 years of diagnosis. Read more about this study

Who is it for?
Ages 20 to 80 years
Conditions the study is for
Efficacy and Safety
What is being tested?
Deep cervical lymph node-vein bypass surgery
Type of treatment
Surgery or procedure
How many people
3 participants
Where
No sites listed yet
Study dates
1 Aug 2024to 1 Aug 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: ALS patients meet to the inclusion and exclusion criteria

Who may be able to join

  • ①diagnosis of probable, clinically probable, clinically probable laboratory-supported, or clinically definite ALS according to the revised El Escorial World Federation of Neurology criteria; ② aged between 20 and 80 years old (inclusive); ③ ALS patients with King's Stage 3-4; ④ body weight not less than 45 kg and body mass index (BMI) not less than 18.0 kg/m2; 5) not currently receiving riluzole or receiving a stable dose of riluzole for at least 4 weeks before screening; Subjects who received riluzole were expected to maintain the same dose throughout the study; ⑦ Subjects' FVC≥60% predicted value after adjusting for sex, age, and height.

Who cannot join

  • ① Refusal to participate; ② Unable to complete MRI scan; ③ significant cognitive impairment, mental illness, epilepsy or other neurodegenerative diseases, substance abuse; ④ recent severe infection or infectious diseases within 4 weeks; ⑤ complicated with other systemic underlying diseases; Any past stem cell or gene therapy for ALS.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Yuanjian Fang, Dr contact

86-18768109541

sandman0506@foxmail.com

About this study

Official title: Evaluation of the Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, affects motor neurons, causing progressive muscle atrophy and weakness. Current treatments are ineffective, with most patients dying within 3-5 years of diagnosis. The disease's exact cause is unclear, but factors such as oxidative stress and protein abnormalities are implicated. Abnormal protein deposits and neurotoxic factors in the brain and spinal cord contribute to ALS pathology. Recent research on the brain's glymphatic-lymphatic system suggests impaired waste clearance may exacerbate ALS. Restoring drainage connections between cervical lymphatic vessels and veins could potentially alleviate neurodegenerative disease progression.

Read the detailed description

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the simultaneous involvement of upper and lower motor neurons, leading to progressive muscle atrophy and weakness in patients. Advanced stages of the disease manifest as symptoms such as swallowing difficulties and respiratory problems. Currently, effective treatments for ALS are lacking, and most patients succumb to the disease within 3 to 5 years of onset. Therefore, there is an urgent need to explore new therapeutic approaches. Although the exact pathogenesis of ALS remains unclear, various mechanisms including oxidative stress, glutamate toxicity, mitochondrial dysfunction, endoplasmic reticulum stress, and protein misfolding are thought to contribute to its development. Pathological findings indicate the presence of abnormal protein deposits, including phosphorylated TDP-43 (Transactive response DNA-binding protein 43 kDa), superoxide dismutase 1 (SOD1), and dysfunctional ribosomal proteins, in the brains and spinal cords of ALS patients. Additionally, elevated levels of neurotoxic factors in the cerebrospinal fluid, such as inflammatory cytokines and reactive oxygen species, have been implicated in the pathogenesis of ALS. Therefore, clearance of abnormal proteins and neurotoxic factors from the brain and spinal cord may have potential therapeutic implications for delaying or preventing neurodegeneration and associated clinical disabilities in ALS patients.

Recently, the discovery of the brain "glymphatic-lymphatic" system has updated our understanding of cerebrospinal fluid circulation. Similar to the peripheral lymphatic circulation, there exists an interstitial fluid circulation system in the brain parenchyma. Studies have revealed that cerebrospinal fluid in the brain parenchyma enters the perivascular spaces surrounding arteries through aquaporin-4 channels on astrocytes and then flows directionally into the perivascular spaces surrounding veins, facilitating waste clearance and nutrient transport in the brain. This phenomenon is known as the glymphatic system. Furthermore, abundant lymphatic vessels have been found adjacent to the dural venous sinuses, participating in cerebrospinal fluid drainage and ultimately draining into the cervical lymph nodes. In animal models of Alzheimer's disease (AD) and Parkinson's disease (PD), impairment of the glymphatic-lymphatic drainage function has been associated with the accumulation of disease-related proteins such as amyloid beta (Aβ), Tau, and alpha-synuclein, and ligating the cervical lymph nodes has been shown to exacerbate disease progression. Clinical studies using magnetic resonance imaging have confirmed the decline in glymphatic-lymphatic system function in patients with AD and PD. Although research on the role and mechanism of the glymphatic-lymphatic drainage system in the occurrence and development of ALS is lacking, magnetic resonance imaging has revealed a significant reduction in glymphatic system function in ALS patients compared to healthy individuals, suggesting an important role of the glymphatic-lymphatic drainage system in the pathogenesis of ALS.

As the final destination of glymphatic-lymphatic cerebrospinal fluid drainage, the cervical lymph nodes play a crucial role in the entire cerebrospinal fluid circulation. With aging, infection, and chronic inflammation, the function of the cervical lymph nodes gradually declines, leading to increased cerebrospinal fluid circulation reflux pressure. Furthermore, the production of large amounts of neurotoxic substances during the progression of AD, PD, and ALS further impairs the function of the cervical lymph nodes, resulting in abnormal accumulation of toxic substances in the brain and disease progression. We speculate that establishing drainage connections between the cervical lymphatic vessels and veins will reduce cerebrospinal fluid circulation pressure in brain tissues, accelerate interstitial fluid reflux, and alleviate the accumulation of metabolic waste, thereby slowing the progression of neurodegenerative diseases.

Being tested
Deep cervical lymph node-vein bypass surgery
Keywords
Amyotrophic Lateral Sclerosis
Medical subject headings
Amyotrophic Lateral Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Deep cervical lymph node-vein bypass surgeryProcedure or surgery

    Deep cervical lymph node-vein bypass surgery, connecting deep cervical lymph node input lymphatic vessel

Study groups in NCT06351735
Study groupRoleWhat they receive
SurgeryPatients undergo deep cervical lymph node-vein bypass surgery
Receives: Procedure: Deep cervical lymph node-vein bypass surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ALSFRS-R scale

    Improvement of ALSFRS-R scale

    Measured: Pre-surgery and post-surgery 1month, 3 months, 6 months and 1 year

  2. Cognitive and Behavioral Scale (CAS)

    Improvement of CAS score

    Measured: Pre-surgery and post-surgery 1month, 3 months, 6 months and 1 year

Secondary outcomes (3)
  1. Baseline of slow vital capacity (SVC)

    Change baseline of SVC

    Measured: Pre-surgery and post-surgery 1month, 3 months, 6 months and 1 year

  2. Evaluation of glymphatic and meningeal lymphatic drainage

    MRI evaluation of glymphatic and meningeal lymphatic drainage

    Measured: Pre-surgery and post-surgery 3 months, 6 months and 1 year

  3. Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5)

    Changes from baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5)

    Measured: Pre-surgery and post-surgery 3 months, 6 months and 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Apr 2024
  2. Study start1 Aug 2024 (estimated)
  3. Primary completion1 Aug 2026 (estimated)
  4. Study completion1 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case crossover
Time perspective
Prospective
Enrolment
3 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06351735
Sponsor's protocol ID
2024-0336
Status last verified
May 2024
First submitted
2 Apr 2024
Last updated
16 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Efficacy and Safety, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 16 May 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Yuanjian Fang, Dr (86-18768109541, sandman0506@foxmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ALSFRS-R scale (time frame: Pre-surgery and post-surgery 1month, 3 months, 6 months and 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in